Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients.
Percutaneous ethanol injection (PEI) was applied to 120 lesions in 95 patients with hepatocellular carcinomas (HCC) smaller than 3 cm in the past 6 years. All main target tumours, in 67 patients who had been followed by sonography for more than 6 months after PEI, decreased in size; 28 tumours (41.8%) became undetectable and have remained so until now. The 1-, 2-, 3-, 4- and 5-year survival rates calculated by the Kaplan-Meier method were 93%, 81%, 65%, 52% and 28% respectively. These survival rates were better than those of patients with HCC smaller than 3 cm who did not receive anticancer treatment (P less than 0.01). The survival of patients of the Child's A or Child's B status was better than that of those with Child's C disease. Recurrence occurred in areas within the liver different from the original lesion in 34% in one year, 61% in two years and 66% in three years after PEI. PEI was then repeated in 61% of such patients.
Ebara
M
M
First Department of Medicine, School of Medicine, Chiba University, Japan.
Ohto
M
M
Sugiura
N
N
Kita
K
K
Yoshikawa
M
M
Okuda
K
K
Kondo
F
F
Kondo
Y
Y
D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015993:Life Tables; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D015996:Survival Rate
D000431:Ethanol